Ulcerative Colitis Market Research Report- Forecast to 2027

Ulcerative Colitis Market Information, by type (Ulcerative Proctitis, Proctosigmoiditis, Left-Sided Colitis, Pancolitis or Universal Colitis, and Fulminant Colitis), by Medication (5-Aminosalicylates, Steroids, Purine Analogs, Immunomodulators, and Biologics) - Forecast to 2027

ID: MRFR/Pharma/1737-HCR | August 2022 | Region: Global | 85 Pages         

Table of Contents

1 INTRODUCTION

1.1 DEFINITION

1.2 SCOPE OF STUDY

1.2.1 RESEARCH OBJECTIVE

1.2.2 ASSUMPTIONS & LIMITATIONS

1.2.2.1 ASSUMPTIONS

1.2.2.2 LIMITATIONS

1.3 MARKET STRUCTURE:

2 RESEARCH METHODOLOGY

2.1 RESEARCH PROCESS:

2.2 PRIMARY RESEARCH

2.3 SECONDARY RESEARCH:

3 MARKET DYNAMICS

3.1 DRIVERS

3.2 RESTRAINTS

3.3 OPPORTUNITIES

3.4 MACROECONOMIC INDICATORS

4 MARKET FACTOR ANALYSIS

4.1 PORTERS FIVE FORCES MODEL

4.2 BARGAINING POWER OF SUPPLIERS

4.3 BARGAINING POWER OF BUYERS

4.4 THREAT OF NEW ENTRANTS

4.5 THREAT OF SUBSTITUTES

4.6 INTENSITY OF RIVALRY

5 GLOBAL ULCERATIVE COLITIS MARKET, BY TYPE

5.1 ULCERATIVE PROCTITIS

5.2 PROCTOSIGMOIDITIS

5.3 LEFT-SIDED COLITIS

5.4 PANCOLITIS OR UNIVERSAL COLITIS

5.5 FULMINANT COLITIS

6. GLOBAL ULCERATIVE COLITIS MARKET, BY MEDICATION

6.1 5-AMINOSALICYLATES

6.2 STEROIDS

6.3 PURINE ANALOG

6.4 IMMUNOMODULATORS

6.5 BIOLOGICS

7. GLOBAL ULCERATIVE COLITIS MARKET, BY REGION

7.1 NORTH AMERICA

7.1.1 INTRODUCTION

7.2 EUROPE

72.1 INTRODUCTION

7.3 ASIA-PACIFIC

7.3.1 INTRODUCTION

7.4 MIDDLE EAST & AFRICA

7.4.1 INTRODUCTION

8. COMPETITIVE LANDSCAPE

8.1 MAJOR STRATEGIES ADOPTED BY MARKET PLAYERS

8..1.1 STRATEGIC PARTNERSHIP

8..1.2 MERGER & ACQUISITION

9 COMPANY PROFILE

9.1 ABBVIE INC.

9.1.1 OVERVIEW

9.1.2 PRODUCT OVERVIEW

9.1.3 FINANCIALS

9.1.4 KEY DEVELOPMENTS

9.2 BAYER AG.

9.2.1 OVERVIEW

9.2.2 PRODUCT OVERVIEW

9.2.3 FINANCIALS

9.2.4 KEY DEVELOPMENTS

9.3 JOHNSON & JOHNSON SERVICES, INC.,

9.3.1 OVERVIEW

9.3.2 PRODUCT OVERVIEW

9.3.3 FINANCIALS

9.3.4 STRATEGY

9.3.5 KEY DEVELOPMENT

9.4 TAKEDA PHARMACEUTICAL COMPANY LIMITED

9.4.1 OVERVIEW

9.4.2 PRODUCT OVERVIEW

9.4.3 FINANCIALS

9.4.4 KEY DEVELOPMENTS

9.5 PFIZER INC.

9.5.1 OVERVIEW

9.5.2 PRODUCT OVERVIEW

9.5.3 FINANCIALS

9.5.4 KEY DEVELOPMENTS

9.6 OTHERS

List of Tables

TABLE 1 GLOBAL ULCERATIVE COLITIS MARKET, BY TYPE, 2013-2022 (USD MILLION)

TABLE 2 GLOBAL ULCERATIVE COLITIS MARKET, BY MEDICATION, 2013-2022 (USD MILLION)

TABLE 3 GLOBAL ULCERATIVE COLITIS MARKET BY REGION 2013-2022 (USD MILLION)

List of Figures

FIGURE 1 RESEARCH PROCESS

FIGURE 2 PORTERS FIVE FORCES MODEL

FIGURE 3 GLOBAL ULCERATIVE COLITIS MARKET, BY TYPE

FIGURE 4 GLOBAL ULCERATIVE COLITIS MARKET, BY MEDICATION

FIGURE 5 GLOBAL ULCERATIVE COLITIS MARKET, BY REGION

FIGURE 6 GLOBAL ULCERATIVE COLITIS MARKET: COMPANY SHARE ANALYSIS, 2015 (%)

Ulcerative Colitis Market

The ulcerative colitis market will witness a growth at a significant CAGR 5.9% with value of USD 10.19 Billion by 2030

Segmentation

by type Ulcerative Proctitis Proctosigmoiditis Left Sided Colitis Pancolitis Or Universal Colitis Fulminant Colitis
by Medication 5 Aminosalicylates Steroids Purine Analogs Immunomodulators Biologics

Key Players

  • Salix Pharmaceuticals
  • Abbott Laboratories
  • Mitsubishi Tanabe Pharma Corporation
  • Celgene Corporation
  • InDex Pharmaceuticals Holding AB
  • BioLineRx Ltd
  • Sanofi Aventis A/S
  • Merck & Co
  • Eli Lilly
  • Johnson & Johnson

Drivers

  • Growing prevalence of bowel disease
  • Increases the production of drugs
Speak to Analyst Request a Free Sample

Ulcerative Colitis Market Overview 


The ulcerative colitis market will witness a growth at a significant CAGR during forecast period. Ulcerative colitis is an inflammatory bowel is a disorder. This ulcer is found in the digestive tracts of individuals. The effects on it are on the inner digestive line of the large intestine. Also, the symptoms of this condition are gradual. Unlike other ulcers, the symptoms are not sudden but will develop over time. The rising cases of ulcerative colitis are surging the market demand. The ulcerative colitis market consists of three major segments. There is a disease and drugs market. Both disease detection and treatment is available for the disorder.


 Ulcerative colitis is considered a chronic disease. The cause of this ulcer in the human body is still unknown. However, research shows that are microbial triggers an immune response may cause this ulcer. Some of the common symptoms of ulcerative colitis are inflammation, diarrhoea, constipation and abdominal pain. As per the international medical report, the UC affects one million in the US. 


The therapy for the UC includes tumour necrosis and inhibitors. Lack of vitamin deficiency is causing ulcerative colitis in low altitudes. The prevalence of this conation is high among tee adults. Also, people quitting smoking develop UC. The biotechnical information says that 9 out of 20 have UC. These statistics show that the therapeutic market and disease segment of the ulcerative colitis market will have massive scope. All these will increase ulcerative colitis market value immensely. 


Covid analysis 


The outbreak of covid 19 is a threat affecting life and business from various ends. This pandemic influences the ulcerative colitis treatment. A medical journal says that reports of covid 19 are more on UC patients. The covid virus is affecting many individuals. However, patients suffering from preexisting health conditions have more impact on the virus. Most of the acute UC patients have covid. It is raising the demand for the treatment of patients with bowel disease.


However, the treatments for other medical conditions are considered non-essential. Only front line treatments such as covid patient care have high importance. The treatment of UC conditions is delayed. Due to social distancing, the treatment of this disease is complex. The rapid spread of the covid virus makes it tough to carry out ulcerative colitis market operations. These factors create a declining trend in the UC market. 


Market dynamics 



  • Crucial market drivers 


The growing prevalence of bowel disease is a crucial driver of ulcerative colitis market. Due to lifestyle changes, vitamin deficiency, autoimmune triggers the cases of ulcerative colitis is rising. As per the national information centre for biotechnology, there are more than 100000 cases of ulcerative colitis every year. 156 out of 291 cases of UC are reported in various regions. It creates attention for more treatment for UC. The surging rate of the condition increases the production of drugs and disease detection. Patients with existing bowel conditions are prone to develop UC. 


This driver of the ulcerative colitis market will contribute to high demand in the forecast period. Further, the rise in the senior population is another crucial driver. The senior population easily develops ulcerative colitis conditions. Individuals, more than 65 years of age have a high rate of bowel disease.


BMC Gastroenterology Journal says that more than 35% of UC patients are above 65. These individuals are fragile and prone to attacks of infections. It is another factor that will increase inflammatory bowel disease treatment market size. These crucial drovers of the make will contribute to high profitability. Also, due to these factors, the expansion rate of ulcerative colitis is immense. 



  • Market growth opportunities 


Research activities in the ulcerative colitis market will create high growth opportunities. The Ulcerative prostate is one of the types of UC. It is the initial stage of this condition. Treating the condition at Ulcerative prostates is possible. Quicker recovery and effortless procedures are involved in treatment. The phase 3 clinical trial is happening to prevent this condition in the early stage. It will provide high exposure for these drugs in global markets.


The research about Ulcerative prostates will have a positive impact on the ulcerative colitis market. Hydrocortisone acetate is a drug for hydrocortisone acetate. The launch of these drugs will attract many end-users. Further, the rise in governmental funding is another factor leading to high growth prospects. The government is investing more in the biologics market. Due to the outbreak of covid 19, the investments for biologics and pharmacies have been raised. This investment will enable new product launches and therapies.


Further, technological advancements will make dugs product effective. New research and drugs production is improved through new technologies. The investment from the government leads to high technological enhancement. This entire factor will create favourable opportunities for ulcerative colitis. The revenue rates and evasion of the ulcerative colitis market will be high due to these factors. 



  • The market restraints 


The patent expiry of drugs is a restraining factor of the ulcerative colitis market. The ulcerative colitis market has few reliable drugs. However, the failure to renew patents leads to failures. The production of drugs contributes the highest revenue to any market. The investments and production of UC drugs are high.


However, patent expiry can affect all these processes; wastage of capital is a major fact that can affect revenue rates. In recent years, the ulcerative colitis market is experiencing high patent failures. It is leading to devastating losses. All these factors can have a negative impact on the ulcerative colitis market growth. 



  • The market challenges 


Stringent governmental rules are a significant challenge in the ulcerative colitis market. The emergence of biosimilar medicines can have a positive impact on the market. They are cost-effective and more accessible. The developing nations have a high demand for this product. However, most of these drugs do not pass governmental guidelines.


Getting approval for any drug from the government is a major factor. Licensed drugs are more reliable and safe. However, these rules by the government are stringent causing much trouble to the market. Also, the unmet clinical need in ulcerative colitis is another challenge of the ulcerative colitis market. More improvement in treatment is essential. All these challenges can hinder the UC market growth.



  • Cumulative growth analysis 


The Ulcerative colitis market trends are perpetual. The prevalence of ulcerative colitis is a demand driving factor of the ulcerative colitis market. Also, the rise in the geriatric population is increasing demand. The rugs segment of the market is witnessing high growth. Anti-inflammatory drugs are much helpful to treat these conditions. Demand for immunosuppressant drugs is continuously rising.


Also, treatment for Ulcerative Proctitis is effective. Treating the condition in the primary stage is leading to fast recovery. However, cases of patent expiry are affecting this market. Also, stringent government rules are delaying new product launches. However, growth is decent for the market due to high research and development.



  • Value chain analysis 


North America will outgrow other regional players with a high ulcerative colitis market share. The presence of top leaders is bringing exceptional changes in the market. Also, awareness about bowel disease is higher.


A higher number of UC cases are recorded in the US. It leads to higher investment for treatment from US and Canada. Funding by the government is rising every year. Also, the invention of new therapeutic is massive in North America. It is a region that will mark the fastest growth rate of the Ulcerative Colitis market. 


Segment overview 


By drugs type 



  • Calcineurin Inhibitors

  • Anti-TNF biologics

  • Anti-Inflammatory Drugs

  • Corticosteroids

  • Immunosuppressant

  • by disease type 

  • Proctosigmoiditis


Fulminant Colitis



  • Pancolitis or Universal Colitis

  • Ulcerative Proctitis

  • Left-sided Colitis


By region 



  • Europe 

  • Asia pacific 

  • North America 

  • Middle East and Africa 

  • South America 


Competitive landscape 


The completion in the Ulcerative colitis is severe. The key players of the market have various strategies. There are products launches, acquisitions, expansion is key strategies in the competitive landscape. The drugs segment of the market will become strong. Research on drugs is high in the upcoming years. 


Regional analysis 


The Ulcerative colitis market is diversified into three major regions. Asia Pacific, Europe and North America are three crucial regional players. North America is the leading region in the UC market. The developments and innovations are diverse. The vast end-users for Ulcerative colitis treatment lead to high demand. Asia pacific is the nest largest region with the fastest growth.


The bowel disease rate is increasing in this region. Fine quality medications and treatment is available in Asia pacific. China, Japan and India have higher audiences and facilities to produce UC drugs. Europe is another region with moderate demand. It is a region that has a high scope of expansion in upcoming years. 


The key players in Ulcerative colitis market are 



  1. Salix Pharmaceuticals

  2. Abbott Laboratories

  3. Mitsubishi Tanabe Pharma Corporation

  4. Celgene Corporation

  5. InDex Pharmaceuticals Holding AB

  6. BioLineRx Ltd 

  7. Sanofi Aventis A/S

  8. Merck & Co

  9. Eli Lilly

  10. Johnson & Johnson

  11. AstraZeneca plc

  12. Ajinomoto Pharmaceuticals Co

  13. Avaxia Biologics Inc


Recent developments 


The key players are making collaborations with biotechnological companies in emerging companies. It will lead to high growth and product launches in high demand areas. 


The key players of the market are developing new drugs for the UC condition. It will lead to new product launches in the market.


Market overview 



  1. Market overview highlights 

  2. Analysis based upon COVID 19

  3. Explanation upon the Market Dynamics

  4. Value chain analysis

  5. Market segmentation overview

  6. The regional analysis

  7. Competitive landscape analysis

  8. Recent Developments



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   2020-2027: Substantial CAGR
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Types and Medication
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Allergan, Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, and Bayer AG, UCB S.A., Perrigo Company plc, Pfizer Inc., Johnson & Johnson Services, Inc., Ferring B.V.
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers

  • Increasing prevalence of ulcerative colitis
  • Higher preference for symptomatic therapeutic
  • Better treatment of inflammatory bowel diseases


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    Ulcerative colitis is a type of inflammatory bowel disease (IBD) that affects the colon and rectum part of human body. Inflammation and ulcers are formed in the innermost lining of the colon and rectum, resulting in the production of pus and mucous in these linings.

    The ulcerative proctitis segment by types and the Biologics segment on the basis of medication hold larger shares in the ulcerative colitis market.

    Increasing prevalence of ulcerative colitis, healthier investments in R&D programs, and rising per capita healthcare expenditure of nations are major drivers of the ulcerative colitis market.

    North America holds the largest share in the global ulcerative colitis market, followed by Europe and the Asia Pacific, respectively.

    AbbVie Inc., Allergan, Inc., Takeda Pharmaceutical Company Limited, UCB S.A., Bayer AG, Perrigo Company plc, Johnson & Johnson Services, Inc., Pfizer Inc., Ferring B.V., Merck & Co. and Janssen Biotech, are some of the major players operating in the ulcerative colitis market.

    ulcerative colitis market is projected grow at approximately 7% CAGR during the assessment period (2016-2022).